REGULATORY

MHLW to Revise Biosimilar Guidelines to Increase Efficiency in Development, Review; Final Draft Expected in FY2019

January 10, 2019
The Ministry of Health, Labor and Welfare (MHLW) plans to update its biosimilar guidelines after a decade with the aim of increasing efficiency in development and reviews, with a study group discussing the revision expected to hammer out a final…

To read the full story

REGULATORY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…